Two Assay Kits for Early ADME Screening, Molecular Devices Corp

Molecular Devices
Corporation (Nasdaq: MDCC) today announced the introduction of two new reagent
products for ADME assay screening-Transil(R) Membrane Affinity and Transil
Human Serum Albumin (HSA) Binding assay kits.


The Transil assay kits provide
lead optimization and high-throughput screening laboratories with fast,
automatable, direct, biologically relevant solutions to increase the
throughput of ADME-related compound profiling.


The Transil Membrane Affinity assay provides data that correlates better
to in vivo studies compared to the more conventional water/octanol
partitioning assays because it uses beads which are coated with a lipid
bilayer that mimic interactions between compounds and cell membranes. The
results are equivalent to the liposome "gold standard" method, without the
tedious preparation of liposomes.


The Transil HSA Binding assay kit makes routine, high-throughput HSA
binding characterization easy because it contains beads which have been coated
with human serum albumin and pre-dispensed into a microplate format. The
pre-dispensed format increases throughput via parallel sample preparation and
assay reading on Molecular Devices' SpectraMax(R) microplate readers.


With the Transil assays, there is virtually no methods development
required, as each kit contains data analysis routines for processing high-
throughput screening of drug candidates for early ADME characterization.
Furthermore, the assays share nearly identical sample workup steps, so steps
developed for one assay are immediately applicable to the other.


Commenting on the launch, Christopher Silva, Director of Marketing for
Life Sciences Products at Molecular Devices stated, "The Transil assay kits
enable screening of compound libraries for membrane affinity and HSA binding
for early ADME properties which are not possible with current low-throughput
methods. These new assays require only one sample concentration, which
simplifies automation. Additionally, turnkey data analysis offers researchers
compound data within hours of synthesis or secondary screening. Because we
have integrated these assays with our SpectraMax(R) microplate reader line, we
have provided a more complete solution to our customers."


The kits are available in two formats for 96- or 384-well microplates.
The "high precision" version is ideal for profiling compounds at the lead
optimization stage of drug discovery; the "high throughput" version allows
characterization of compound libraries.


Molecular Devices Corporation is a leading supplier of high-performance
bioanalytical measurement systems that accelerate and improve drug discovery
and other life sciences research. The Company's systems and consumables
enable pharmaceutical and biotechnology companies to leverage advances in
genomics, proteomics and parallel chemistry to facilitate the high-throughput
and cost-effective identification and evaluation of drug candidates. The
Company's solutions are based on its advanced core technologies that integrate
its expertise in engineering, molecular and cell biology and chemistry.
Molecular Devices enables its customers to improve research productivity and
effectiveness, which ultimately accelerates the complex process of discovering
and developing new drugs.


This press release contains "forward-looking" statements, including
statements related to the prospects for or potential customer use of the
Transil Membrane Affinity and Transil Human Serum Albumin (HSA) Binding assay
kits. Any statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements. Words such
as "believes," "anticipates," "plans," "expects," "will," and similar
expressions are intended to identify forward-looking statements. There are a
number of important factors that could cause the results of Molecular Devices
Corporation to differ materially from those indicated by these forward-looking
statements, including, among others, risks related to the development of new
products and other risks detailed from time to time in the Company's SEC
reports, including its Annual Report on Form 10-K for the year ended December
31, 2004. Molecular Devices Corporation does not undertake any obligation to
update forward-looking statements.


Molecular Devices Corporation

moleculardevices